Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) (Ad5-nCoV) in Canada
Condition: COVID-19 Interventions: Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector); Biological: Placebo Sponsors: CanSino Biologics Inc.; Institute of Biotechnology, Academy of Military Medical Sciences. PLA of China; Canadian Center for Vaccinology Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Academies | Adenoviruses | Biotechnology | Canada Health | China Health | Clinical Trials | Coronavirus | COVID-19 | Research | Vaccines